doi: 10.1042/cs0390223
While losing weight is an effect of the drug itself, its also due to diet changes caused by GLP-1s (3)
Early Discoveries, With More to Come So far, GLP-1s, first approved 20 years ago for type 2 diabetes and later obesity, have shown potential in treating a surprisingly wide range of conditions, such as heart disease, Parkinsons, Alzheimers, sleep apnea, and liver disease
These interconnected challenges led us to develop a comprehensive approach focusing on health, wealth, and purpose
CrossRef Aroda VR, Bauer R, Christiansen E, et al
When Semaglutide Resistance Means You Need a Different Compound If you've used semaglutide consistently for 34 months at appropriate doses and experienced no meaningful weight loss, your genetic profile may indicate better success with tirzepatide or a dual-mechanism approach